IRCT20210420051023N1 IRCT 2021-09-08 Birjand University of Medical Sciences Effects of Sertralin and Duloxetin in treatment of IBS Comparison of anti-anxiety medication (Sertraline and Duloxetine) on anxiety and gasterointestinal symptoms of irritable bowel syndrome patients 2021-09-21 anticipated 192 Complete https://irct.ir/trial/55768 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants in the study will be randomly divided into three intervention groups: sertraline (A), Duloxetine (B) or antispasmodic, and symptomatic treatment of diarrhea or constipation (C) using the blocking method. First, various triple blocks are created using sealed envelopes (ABC, ACB, BAC, BCA, CAB, CBA). One of these blocks is selected randomly and according to the order mentioned in the selected block, patients will be allocated into one of three groups A, B or C. Then randomization will be performed for other patients in the same way, Blinding description: Outcome Evaluator: The study facilitator (medical student) will perform the necessary evaluation without knowing the type of medication received by the patients and will be recorded in a checklist designed for this purpose. Patients: The patients participating in the study are not aware of their group, so the drugs are packaged in the same package and given to patients by the pharmacy. 3 Irritable bowel syndrome. Intervention 1: Intervention group: Intervention group 1 patients who are given sertraline 50 mg daily (Obidi Pharmaceutical Company made in Iran) for one month. Intervention 2: Intervention group: Intervention group 2 patients who are given duloxetine 60 mg daily (Obidi Pharmaceutical Company made in Iran) for one month. Intervention 3: Control group: Intervention group: 3 patients who are given antispasmodic medication daily (Moburin with a dose of 135 mg made by Alhawi Company of Iran) and symptomatic treatment of diarrhea or constipation for one month. Yes - There is a plan to make this available What will be shared: Only part of the data such as information about the main outcome or the like can be shared. When: Access period starts 3 months after the results are published To whom: Only for researchers working in academic and scientific institutions Conditions: The use of documents is permitted only for use in helping patients Where to obtain: enayat moghri How to obtain: Submit a request for the use of documents or data files Comments: